SUBSCRIBE
SUBSCRIBE
News   Business   Deals

Ambrilia Biopharma Inc. Sells Prostate Cancer Drug Candidate to Kotinos Pharmaceuticals Inc. for up to $15 Million

July 17, 2009 | 
1 min read
Bookmark and Share

Reuters -- Small Canadian biotech company Ambrilia Biopharma Inc said it agreed to sell its experimental prostate cancer drug, PCK3145, to Kotinos Pharmaceuticals Inc.
Mergers & acquisitions Australia
MORE ON THIS TOPIC
Hand shaking print screen on wooden block cube between human icon for business deal and agreement concept.
Deals
Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs
September 24, 2026
 · 
2 min read
 · 
Gabrielle Masson
Business people shaking hand in China.
China
Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare
September 24, 2026
 · 
1 min read
 · 
Tristan Manalac
Creative abstract template collage of hands eating golden coins earning money meal unusual fantasy billboard comics.
Venture capital
AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease push
September 23, 2026
 · 
1 min read
 · 
Annalee Armstrong
Opportunity of winning. man sees a illuminated trophy door. vector
autoimmune disease
Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren’s study
September 23, 2026
 · 
2 min read
 · 
Tristan Manalac